ER stress and Rho kinase activation underlie the vasculopathy of CADASIL

Karla B. Neves, … , Keith Muir, Rhian M. Touyz


Graphical abstract

Find the latest version:

http://jci.me/131344/pdf
ER stress and Rho kinase activation underlie the vasculopathy of CADASIL

*Karla B Neves¹, *Adam P Harvey¹, Fiona Moreton², Augusto C Montezano¹, Francisco J Rios¹, Rhéure Alves-Lopes¹, Aurelie Nguyen Dinh Cat¹, Paul Rocchicciolli³, Christian Delles¹, Anne Joutel⁴, Keith Muir², Rhian M Touyz¹,⁵. *Co-first authors

¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK;
²Institute of Neuroscience & Psychology, University of Glasgow & Queen Elizabeth University Hospital; ³Golden Jubilee National Hospital, Clydebank, UK;
⁴Institute of Psychiatry and Neurosciences of Paris, Inserm, Paris Descartes University, France; ⁵Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Canada.

Conflicts of interest: There are no conflicts of interest to declare.

To whom correspondence should be addressed:

Rhian M Touyz MD, PhD
Institute of Cardiovascular and Medical Sciences,
University of Glasgow,
126 University Place, Glasgow, G12 8TA,
Glasgow, UK
Phone: + 44 (0)141 330 7775/7774, Fax: + 44 (0)141 330 3360,
Email: Rhian.Touyz@glasgow.ac.uk
Abstract

CADASIL leads to premature stroke and vascular dementia. Mechanism-specific therapies for this aggressive cerebral small vessel disease are lacking. CADASIL is caused by NOTCH3 mutations that influence vascular smooth muscle cell (VSMC) function through unknown processes. We investigated molecular mechanisms underlying the vasculopathy in CADASIL focusing on ER stress and RhoA/Rho kinase (ROCK). Peripheral small arteries and VSMCs were isolated from gluteal biopsies of CADASIL patients and mesentery of TgNotch3R169C mice (CADASIL model). CADASIL vessels exhibited impaired vasorelaxation, blunted vasoconstriction and hypertrophic remodelling. Expression of NOTCH3 and ER stress target genes was amplified and ER stress response, Rho kinase activity, superoxide production and cytoskeletal-associated protein phosphorylation were increased in CADASIL, processes associated with Nox5 upregulation. Aberrant vascular responses and signalling in CADASIL were ameliorated by inhibitors of Notch3 (gamma-secretase inhibitor), Nox5 (mellitin), ER stress (4-PBA) and ROCK (fasudil). Observations in human CADASIL were recapitulated in TgNotch3R169C mice. These findings indicate that vascular dysfunction in CADASIL involves ER stress/ROCK interplay driven by Notch3-induced Nox5 activation and that NOTCH3 mutation-associated vascular pathology, typical in cerebral vessels, also manifests peripherally. We define Notch3-Nox5/ERstress/ROCK signaling as a novel putative mechanism-specific target and suggest that peripheral artery responses may be an accessible biomarker in CADASIL.

Key words: Notch3, small arteries, oxidative stress, signal transduction, vascular dementia, stroke, fasudil, 4-PBA
Introduction

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most aggressive form of small vessel disease of the brain leading to premature stroke and vascular dementia (1). It is caused by NOTCH3 mutations (2) and is the commonest monogenetic form of stroke (3). CADASIL is a devastating condition because it affects adults in their prime years with the age of onset about 30 years, it is progressive, it is commonly associated with depression and psychiatric disorders and there are no mechanism-specific treatments (1-4).

Although CADASIL manifests clinically as a vascular disease of the brain, all small and medium-sized arteries are likely to be affected by CADASIL-causing NOTCH3 mutations (5, 6). It is therefore possible that these mutations also cause vascular abnormalities peripherally. However, there is a paucity of information about the systemic microvasculature in CADASIL with some studies reporting endothelial dysfunction in peripheral and retinal arteries while others demonstrating normal endothelial function with altered vascular reactivity (7-12).

Notch3, comprised of an extracellular domain (ECD), a transmembrane and an intracellular domain, regulates the structural and functional integrity of small arteries. Unlike other Notch isoforms (Notch1, 2, 4), Notch3 is expressed almost exclusively in vascular smooth muscle cells (VSMCs) (13). CADASIL-causing NOTCH3 mutations lead to progressive degeneration of VSMCs, accumulation of abnormal protein (granular osmiophilic material (GOM)) around VSMCs and vascular dysfunction (2, 14). In the brain, these processes present as subcortical lacunas and white matter injury and manifest clinically as premature stroke, dementia, cognitive decline and migraines (1, 3, 15). While the clinical characteristics of CADASIL are well defined, the molecular and cellular processes underlying the vasculopathy are poorly understood.
Putative mechanisms have been studied in experimental models of CADASIL (TgNotch3\textsuperscript{R169C} mice) and immortalized human cell lines. Studies in TgNotch3\textsuperscript{R169C} mice demonstrated that cerebrovascular dysfunction is associated with upregulation of voltage-dependent potassium (K\textsubscript{v1}) channels, blunted membrane depolarization and reduced myogenic tone due to increased levels of metallopeptidase inhibitor TIMP3 (16-18). To date, these processes have not been demonstrated in human disease. Cell-based studies using cultured umbilical VSMCs from a CADASIL patient reported increased expression of proteins involved in protein degradation/folding, cytoskeletal organisation, contraction and cell stress (19). In human induced pluripotent stem cells generated from CADASIL somatic cells and in skin fibroblasts of CADASIL patients, increased platelet-derived growth factor (PDGF) signalling, enhanced TGFβ expression, endoplasmic reticulum (ER) retention of mutant Notch3 aggregates and oxidative and ER stress have been described (20-24).

ER stress is a cellular response to the accumulation of unfolded/misfolded proteins in the ER and has been implicated in vascular dysfunction in cardiovascular disease (25, 26). Beyond its role in the processing of cellular proteins, ER stress influences VSMC function through its effects on Ca\textsuperscript{2+} handling, oxidative stress and signalling molecules, including Rho kinase (27). Calcium and RhoA/Rho kinase are critically involved in controlling VSMC contraction, migration, growth and cytoskeletal organisation and increased Rho kinase activity has been demonstrated in many models of vascular dysfunction (28, 29).

A relationship between ER stress and Rho kinase has been demonstrated in VSMCs (30) and experimental models of vascular damage, where the ER stress response promotes activation of Rho kinase (30, 31). These phenomena may be regulated by Notch3-dependent processes because i) Notch3 associates with the protein-folding chaperone GRP78/BiP in the ER (32), mutations in Notch3 cause formation and retention of aggregates in the ER (23) and Notch3 modulates vascular RhoA/Rho kinase signalling (33). Accordingly, it is plausible that
abnormal signalling through Notch3 and its downstream targets play a role in vascular injury and dysfunction in CADASIL.

We hypothesised that aberrant Notch3 function promotes ER and oxidative stress and activation of RhoA/Rho kinase, which alter VSMC growth and cytoskeletal organisation, processes leading to impaired vascular function in CADASIL. ER stress and Rho kinase are clinically important druggable targets because FDA-approved drugs that inhibit these targets are available. Uniquely, we interrogated these processes in disease-appropriate small arteries and VSMCs from clinically phenotyped CADASIL patients. We also used a reverse-translation approach in transgenic mice (TgNotch3\textsuperscript{R169C}) that express the CADASIL-causing Notch3(R169C) mutant protein (6).
Results

Clinical features of subjects

We studied twenty CADASIL patients (aged 30-62 years, 55% female), who carry between them 13 different NOTCH3 genetic mutations, all of which involve cysteine residues in exons 2 to 6. The clinical features, genetics and demographic of the CADASIL patients are reported in supplementary table 2. Eleven normotensive, healthy subjects on no medication and with no history of cardiovascular disease (34-58 years, 60 % female) were studied as controls. Pulse wave velocity which is an important clinical parameter to evaluate cardiovascular risk, was recorded in patients (7.84 ± 0.34 m/sec) and found to be similar to published age-related normal values (34) and not different to our previously reported results in CADASIL patients (15). These findings indicate that the stiffness of large arterial vessels is not altered in CADASIL.

Altered function, structure and mechanical properties of peripheral small arteries in CADASIL

Small resistance arteries from gluteal biopsies were studied by wire and pressure myography to assess vascular contraction, relaxation and structural properties. In vessels from healthy control subjects, maximal agonist-induced vasorelaxation (endothelium-dependent and independent) and vasoconstriction were ~100% (Figure 1) as we and others have previously reported (35, 36). In small arteries from CADASIL patients, acetylcholine (ACh)-induced vasorelaxation (endothelium-dependent) was significantly impaired with maximal dilatory responses of 20-30%, compared with 90-100% in control vessels (Figure 1A). These effects in CADASIL were slightly ameliorated in vessels pre-treated with the ROS scavenger N-Acetyl Cysteine (NAC) (Figure 1B). Sodium nitroprusside (SNP)-induced vasorelaxation (endothelium-independent) (Figure 1C) was also significantly reduced relative to controls. Contractile responses to phenylephrine (PE) were decreased in CADASIL vessels compared
with vessels from healthy controls (Figures 1D). Similar attenuated vasoconstriction was also evident for angiotensin II (Ang II), where maximal contractile responses were decreased in CADASIL vessels (Supplemental figure S1).

Vascular structure was altered in CADASIL subjects. While there were no changes in the external and internal diameters of CADASIL vessels relative to control vessels (Figures 2A, 2B), the vascular wall (media) thickness and the media:lumen ratio were significantly greater in CADASIL vessels compared to controls (Figures 2C, 2D), suggestive of hypertrophic remodelling (37). Mechanical properties (circumferential vessel wall stress, strain) were studied in pressurized vessels. Changes in circumferential vessel wall stress and strain under increasing intraluminal pressure showed a significant right-ward shift in CADASIL versus control arteries, indicating reduced stiffness, or increased elasticity, in CADASIL vessels (Figures 2E, 2F).

**VSMC phenotype is altered in CADASIL**

In order to further investigate the mechanisms underlying the vascular changes observed in CADASIL small arteries, primary culture VSMCs obtained from CADASIL vessels were studied. CADASIL VSMCs exhibited increased rates of cell growth, as measured by carboxyfluorescein succinimidyl ester (CSFE) and flow cytometry (Supplementary figures S2A, S2B) and by the increased expression of proliferating cell nuclear antigen (PCNA), a marker of cell proliferation (Supplementary figure S2C). Caspase 3/7 activity, a molecular index of apoptosis, was also elevated in CADASIL VSMCs compared to controls (Supplementary Figure S1D). Phalloidin staining showed marked alteration of actin cytoskeletal fibres in CADASIL VSMCs (Supplementary Figure S3). Together these data suggest a proliferative and pro-apoptotic profile with cytoskeleton disorganization in CADASIL VSMCs.

**Increased NOTCH3 signalling in CADASIL VSMCs**
To evaluate whether *NOTCH3* mutation is associated with impaired Notch3 function and signalling, we assessed Notch3 receptor and Notch3 extracellular domain (ECD, Notch3\(^{ECD}\)) levels as well as *NOTCH3*-downstream gene targets in VSMCs from control and CADASIL patients. CADASIL VSMCs exhibited increased Notch3\(^{ECD}\) accumulation (Figures 3A). Protein levels of Notch3 transmembrane/cytosolic fragment (TMIC) and *NOTCH3* receptor gene expression were increased in CADASIL VSMCs relative to controls (Figures 3B, 3C). Following receptor cleavage, the Notch3 intracellular (ICD, Notch3\(^{ICD}\)) translocates to the nucleus, where it activates the transcription of Notch target genes, including hairy/enhancer-of-split related with YRPW motif-like protein (*HEYL*), nuclear receptor interacting protein 2 (Nrip2) and glutamate receptor–interacting protein 2 (Grip2), which are involved in cell fate regulation. *HEYL* mRNA expression was increased in CADASIL VSMCs (Figure 3D). Expression of *NOTCH3* and *HEYL* mRNA in CADASIL VSMCs was decreased to control levels when cells were pre-treated with a gamma-secretase inhibitor (GSI), which inhibits Notch3 activation (Figures 3C, 3D). No significant changes were observed for *Nrip2* and *Grip2* mRNA levels (Figures 3E, 3F).

**Altered Ca\(^{2+}\) transients and augmented Rho kinase activity and ER stress in CADASIL**

To investigate possible mechanisms that underlie the vascular functional abnormalities observed in CADASIL vessels, we measured changes in agonist-stimulated Ca\(^{2+}\) responses and activation of the Rho kinase and ER stress pathways in VSMCs. As shown in figure 4A, VSMC Rho kinase activity, as assessed by ELISA, was found to be increased in CADASIL VSMCs, relative to controls. This increased Rho kinase activity was associated with augmented protein expression of the Rho-associated kinase Rho kinase 2 (ROCK2), which was abolished when Notch signalling was inhibited by a gamma-secretase inhibitor (Figure 4B). Protein expression of the other Rho-associated kinase, ROCK1, was unchanged (Figure 4C). Ca\(^{2+}\) transients were also altered in CADASIL patient-derived VSMCs, in which the
agonist-induced Ca$^{2+}$ response was acute and not sustained, compared with control VSMC (Figure 4D, 4E). This difference in the Ca$^{2+}$ transient was reflected by reduced area under the curve in the CADASIL group, likely indicating decreased cytosolic [Ca$^{2+}$].

As shown in figure 5, CADASIL patient VSMCs exhibited increased transcription of ER stress genes: Autocrine Motility Factor Receptor (AMFR6), ER Degradation Enhancer Mannosidase Alpha-Like 1 (EDEM1), F-Box Protein 6 (FBXO6), Membrane-Bound Transcription Factor (MBTPS1), VCP-Interacting Membrane Protein (VIMP) and Synoviolin 1 (SYVN1) (Figures 5A-5F). CADASIL VSMCs also showed an increase in protein expression of the Binding immunoglobulin protein (Bip) (Figure 5G), a molecular chaperone located in the ER and involved in ER protein handling. Increased BIP expression was reduced in CADASIL cells pre-treated with the gamma-secretase inhibitor. The ER stress response is typically associated with oxidative stress and, as shown in figure 6, ROS production was significantly increased in CADASIL VSMCs compared with controls (Figure 6B, 6C). Together these data indicate that NOTCH3 mutations in CADASIL VSMCs manifest as a gain-of-function and increased activation of Notch3, with associated upregulation of Rho kinase, ER stress responses and oxidative stress.

**Nox5-derived ROS is an upstream regulator of Rho kinase and ER stress in CADASIL VSMCs.**

Both Rho kinase activation and ER stress are redox-sensitive processes. Accordingly, we questioned whether ROS play a role in Rho kinase activation and the ER stress response in CADASIL VSMCs. As demonstrated in figure 6A, expression of the major vascular Nox-producing oxidase in humans, Nox5, is increased in CADASIL. This was associated with significantly increased ROS generation (Figures 6B, 6C), effects that were attenuated by GSI and mellitin (Figures 6B, 6C), indicating that oxidative stress in CADASIL involves Notch3 and Nox5 and that Nox5 is downstream of Notch3. The increase in Bip expression observed
in CADASIL VSMCs was also inhibited by mellitin (Figure 6D), suggesting that the ER stress observed in CADASIL is associated with Nox-5.

**Interplay between NOTCH3, Rho kinase and ER stress**

To investigate potential interactions between Rho kinase and ER stress in CADASIL, we incubated VSMCs obtained from CADASIL patients and control subjects with 4-phenylbutyrate acid (4-PBA, ER stress inhibitor) or with fasudil (Rho kinase inhibitor). Both 4-PBA and fasudil reduced expression of *NOTCH3* target genes *HEYL* (Figure 7A) and *HES5* (Figure 7B) in CADASIL VSMCs, an effect that was absent in control VSMCs. 4-PBA and fasudil also reduced expression of the ER stress markers, *AMFR6* (Figure 7C) and *EDEM1* (Figure 7D) in CADASIL, with no effect observed on control VSMCs. Treating CADASIL VSMCs with 4-PBA also significantly reduced levels of Bip (Figure 7E), and activity of Rho kinase (Figure 7F). 4-PBA did not significantly alter Ca\(^{2+}\) transients (Supplementary figure S4).

**Rho kinase, ER stress and VSMC function**

To determine whether the Notch3/Rho kinase/ER stress network contributes to the altered VSMC phenotype in CADASIL, we assessed effects of 4-PBA and fasudil on VSMC proliferation, apoptosis and cytoskeletal regulation. Incubating CADASIL VSMCs with 4-PBA and fasudil did not influence their proliferation or apoptosis (Supplementary figures S5A, S5B) but ameliorates activation of cytoskeletal regulatory proteins. Specifically, increased phosphorylation of vimentin and cofilin in CADASIL VSMCs was normalized by 4-PBA and fasudil (Figures 8A, 8B). In contrast, phosphorylation of filamin, another actin-binding protein, was not altered in CADASIL cells, and 4-PBA and fasudil had no effect on its expression or phosphorylation (Figure 8C). These data suggest that ER stress and Rho kinase play an important role in VSMC cytoskeletal regulation, without significantly influencing cell growth in CADASIL.
Altered function of mesenteric arteries in TgNotch3R169C mice

TgNotch3R169C mice were used as an experimental model to further dissect molecular pathways identified in CADASIL patients. As shown in supplementary table 3, body weight and systolic blood pressure of TgNotch3R169C mice were similar to wild-type (TgNotch3WT) controls. Cardiac function and structure were similar between groups with no differences in heart weight, fractional shortening, mitral valve E/A and anterior wall thickness between TgNotch3R169C and control mice (Supplementary table 3).

We next assessed vascular function in small resistance arteries of TgNotch3WT and TgNotch3R169C using wire myography. Similar to what we observed in CADASIL patients, vessels from TgNotch3R169C mice showed significant reduction in SNP-induced vasorelaxation (Figure 9A) compared to responses in TgNotch3WT mice. These responses were restored when arteries were exposed to fasudil (Figure 9B) and 4-PBA (Figure 9C). No changes were observed in vessels from TgNotch3WT mice incubated with fasudil and 4-PBA.

We also investigated vascular structure by pressure myography. The external and internal diameters, cross-sectional area, wall thickness, and the media:lumen ratio of vessels in TgNotch3R169C mice were similar to those in TgNotch3WT vessels (Figures 9D-9H).

Increased Notch3 signalling, Rho kinase and ER stress-related protein expression in TgNotch3R169C mice

Expression of Notch3 transmembrane/cytosolic fragment (TMIC) was increased in TgNotch3R169C vessels compared to TgNotch3WT controls (Figure 10A). Notch3 mRNA expression was also increased in aorta and mesenteric arteries from TgNotch3R169C mice compared to control wild-type mice (Figures 10B, 10C, respectively). Transcription of the downstream Notch3 target gene Heyl was increased in both aorta (Figure 10D) and mesenteric arteries (Figure 10E) from TgNotch3R169C mice compared to controls, while Hes5 gene expression was unchanged in TgNotch3R169C mice (Figures 10F, 10G). As shown in
Figures 11A and 11D, respectively, vascular expression of Bip and the Rho guanine nucleotide-exchange factor (GEF), p115, was increased in TgNotch3R169C mice compared to TgNotch3WT. Gene expression of Larg and Pdz was unchanged in TgNotch3R169C mice (Figures 11B, 11C).
Discussion

Molecular processes underlying the vasculopathy in CADASIL are elusive. To address this, we investigated disease-appropriate human tissue from clinically phenotyped CADASIL patients and interrogated mechanisms at the molecular, cellular and vascular levels. Major findings from our study show that small arteries in CADASIL exhibit functional and structural alterations defined by reduced vasoreactivity, hypertrophic remodelling and decreased stiffness, processes linked to increased VSMC proliferation and apoptosis and cytoskeletal reorganisation. At the molecular level, vascular abnormalities in CADASIL were associated with Notch3 gain-of-function, Nox5-induced oxidative stress, ER stress response and Rho kinase activation. Perturbed signalling and activation of cytoskeletal-associated proteins in CADASIL were ameliorated by 4-PBA and fasudil, highlighting a role for ER stress and Rho kinase in the vasculopathy of CADASIL. These phenomena in human studies were recapitulated and further interrogated in TgNotch3<sup>R169C</sup> mice, where vascular dysfunction was normalised by inhibitors of 4-PBA and fasudil. Our novel findings identify important interplay between Notch3, ER stress and Rho kinase, in part through Nox5-derived ROS, that underlie small vessel injury and dysfunction in CADASIL. These candidates may be potential mechanism-specific druggable targets in the disease.

We provide direct evidence that CADASIL-causing NOTCH3 mutations have vascular manifestations beyond the cerebral vasculature and that peripheral small arteries are abnormal in CADASIL. Functionally, vasorelaxation was reduced and agonist-induced vasoconstriction was attenuated in CADASIL. VSMC contraction and relaxation are characteristically regulated by increased [Ca<sup>2+</sup>]<sub>i</sub>, which triggers contraction (38). Our findings of reduced agonist-stimulated Ca<sup>2+</sup> transients indicate perturbed contractile signalling in CADASIL VSMCs. Mechanisms whereby mutant Notch3 influences these processes are unclear but alterations in Ca<sup>2+</sup> influx and efflux may be important since Notch3 regulates
Ca\(^{2+}\) channels (store-operated Ca\(^{2+}\) entry, canonical transient receptor potential (TRPC6)) (39). Structurally CADASIL arteries exhibited hypertrophic remodelling (increased media:lumen ratio) with reduced stiffness possibly due to cytoskeletal reorganization and dysregulated cell growth. Increased apoptosis was associated with VSMC growth in CADASIL and may represent attempts to counteract excessive proliferation and vascular remodelling. On the other hand, VSMC proliferation may be a response to cell death and apoptosis. Changes in the fine-tuning of cell growth and apoptosis probably contribute to structural vascular remodelling in CADASIL. Alteration in the VSMC phenotype in CADASIL may also be a direct effect of Notch3 activation because Notch3 plays an important role in phenotypic switch-type behaviour of vascular cells, as demonstrated by a computational framework of Notch signalling (40). Confirming activation of Notch3 signalling in CADASIL cells was increased expression of NOTCH3 targets, HeyL and Hes, effects that were attenuated by gamma-secretase inhibition.

Our findings of reduced vasoreactivity in peripheral arteries support our previous studies in cerebral arteries in CADASIL (15). Others have also reported decreased cerebrovasodilation in CADASIL patients challenged with CO\(_2\) and acetazolamide (41). These vascular abnormalities likely contribute to brain hypoperfusion injury and to the consequent stroke and dementia that characterise CADASIL. However, it still remains unclear why CADASIL is not associated with systemic vascular disease (42), especially in light of the significant vascular dysfunction and arterial remodelling in the peripheral circulation as we demonstrate here. It might be that systemic vasoprotective mechanisms, involving the sympathetic nervous system, differentially influence cerebral and peripheral arteries. It may also be possible that reduced vasoconstriction counteracts impaired vasodilation in an attempt to maintain vascular tone. This awaits confirmation as yet undefined mechanisms are also likely to be important. CADASIL is typically a disease of small vessels, and in line with previous
studies, vascular function of large arteries, as assessed by PWV, was not altered in CADASIL patients in our study.

Experimental models of human disease, specifically TgNotch3R169C mice that recapitulate salient properties of CADASIL, including cerebrovascular structural alterations, reduced vasodilation, and diminished pressure-induced vasoconstriction (6), have been used to dissect underlying mechanisms. Pathophysiological processes associated with cerebrovascular dysfunction in TgNotch3R169C mice include a Kv1 channelopathy and increased levels of extracellular matrix proteins, including TIMP3 (6, 16-18, 43). These processes have not been demonstrated in human disease. Molecular systems that have been implicated in CADASIL patients include decreased TRPV1 channel expression, altered PDGF signalling and oxidative stress (20-24). However, these studies were performed in human cell lines from the umbilical cord, skin fibroblasts and induced pluripotent stem cells, which have little relevance in the vasculopathy of CADASIL (19-22).

In a proteomic screen in VSMCs from a CADASIL patient, expression of proteins involved in protein degradation/folding, cytoskeletal organisation, contraction and cell stress was increased (19). Many of these processes are associated with ER stress, which has also been demonstrated in CADASIL cells (23, 24) and in vascular dysfunction associated with hypertension (44) and diabetes (45). In our study expression of ER stress genes namely AMFR6, EDEM1, FBXO6, MBTPS1, VIMP and SYVN was increased in CADASIL VSMCs. In addition, VSMC expression of Bip, a chaperone molecule involved in the ER unfolded protein response was increased in CADASIL patients, a phenotype that was recapitulated in TgNotch3R169C mice. AMFR6, EDEM1 and FBXO6 participate in protein degradation, while MBTPS1, VIMP and SYVN1 play a role in protein removal (46). Associated with ER stress in CADASIL VSMCs, was upregulation of Rho kinase, which itself has been shown to influence ER stress (30). RhoA/Rho kinase signalling influences VSMC contraction, growth
and cytoskeletal organisation and is an important regulator of Ca\textsuperscript{2+}-independent vasocontraction and endothelium-independent vasorelaxation, processes that were impaired in CADASIL VSMCs. Increased Rho kinase activity has been demonstrated in models of vascular dysfunction (47, 48) and has been suggested as a therapeutic target in cerebral vascular disorders in patients with ischaemic stroke and cerebrovascular disorders (49, 50). We advance this notion and suggest that Rho kinase plays a role in VSMC dysfunction in CADASIL. This is supported by studies showing that Notch3 is an upstream regulator of RhoA/Rho kinase and is involved in resistance artery mechano-transduction and pressure-induced (myogenic) tone (33, 51).

Pharmacological inhibition of Notch activation with GSI decreased expression of Bip and Rho kinase confirming Notch3 is an upstream regulator. The functional significance of these systems was further explored using 4-PBA and fasudil, which corrected many of the abnormal molecular changes in CADASIL VSMCs, including Notch3 downstream target genes, Rho kinase activity and ER stress markers. In addition, in CADASIL VSMCs, 4-PBA and fasudil normalized increased phosphorylation of cytoskeletal-associated proteins, vinculin and cofilin, which are structural proteins that influence cytoskeletal organization. These inhibitors had no effect on VSMC proliferation or apoptosis but ameliorated the cytoskeletal remodelling defects in CADASIL, indicating that ER stress- Rho kinase-mediated functional responses are not generalised phenomena, but are highly specific. Of significance, 4-PBA reduced Rho kinase activity, while fasudil decreased Bip expression, indicating crosstalk between ER stress and Rho kinase in the context of increased Notch3 activity in CADASIL. Interactions between these pathways have been reported in other systems, as evidenced by i) reduction in renal Notch signalling in response to Rho kinase inhibition (52), ii) Notch3-induced activation of Rho kinase in pluripotent stem cells (51), iii)
decreased vascular Rho A signalling in Notch3-deficient mice (33), and iv) amelioration of ER stress by Rho kinase inhibitors (30) and v) Notch3-association with the ER stress (32).

We further explored putative upstream systems regulating vascular signalling in CADASIL, focusing on oxidative stress, since Rho kinase and ER stress response are highly redox-sensitive. Similar to what has been demonstrated previously in other small vessel diseases of the brain (53-56), we found increased ROS production in CADASIL VSMCs. Moreover, we identified Nox5, the major Nox isoform responsible for vascular ROS generation in humans, as a key source of vascular oxidative stress in CADASIL. Hence, we define a novel system whereby mutant Notch3 activation induces Nox5-derived ROS generation that influences ER stress response and vascular function in human CADASIL. Mechanisms whereby Notch3 regulates Nox5 expression/activity are unclear but may relate to increased activation of Notch3-regulated transcription factors, which could influence Nox5 processing.

To further back the notion that Rho kinase and ER stress directly influence vascular dysfunction in CADASIL and as a proof of concept, we performed vascular functional studies in our pre-clinical mouse model of CADASIL and showed that both fasudil and 4-PBA ameliorate impaired vasorelaxation. The experimental model was studied to facilitate easy access of sufficient vascular tissue, which is a limitation in human studies. Whether similar effects observed in CADASIL mice also occur in intact vessels from CADASIL patients awaits confirmation, but our molecular studies in human CADASIL VSMCs are certainly supportive.

In conclusion, we demonstrate that peripheral small arteries from CADASIL patients exhibit endothelial dysfunction, impaired endothelium-independent vasorelaxation, hyporeactivity and altered structural and mechanical properties, processes associated with altered VSMC growth and cytoskeletal reorganisation and perturbed vascular signalling
involving Notch3 gain-of-function, Nox5-derived ROS, ER stress and Rho kinase activation. Using a reverse translational approach, observations in CADASIL patients were recapitulated in TgNotch3\textsuperscript{R169C} mice. Our findings identify a novel Notch3-regulated pathway involving interplay between the ER stress response and Rho kinase in the vasculopathy of CADASIL. Inhibiting ER stress and Rho kinase with FDA-approved pharmacological agents, 4-PBA and fasudil, ameliorated vascular dysfunction in CADASIL, highlighting these pathways as potentially beneficial therapeutic targets. Our study also shows that vascular alterations in CADASIL manifest peripherally and are not only confined to the cerebral vasculature, suggesting that peripheral artery responses may be an accessible biomarker in CADASIL.
Methods

Study approval

Ethics approval for the use of human samples was obtained from the West of Scotland Research Ethics Service (WS/12/0294) and from the Ethics Board of the Ottawa Hospital Research Institute (OHRI), Canada (#997392132). Written informed consent was obtained for all study participants in accordance with the Declaration of Helsinki. All experimental protocols on mice were performed in accordance with the Ethical Principles in Animal Experimentation adopted by the West of Scotland Research Ethics Service and in accordance with the United Kingdom Animals Scientific Procedures Act 1986 and ARRIVE Guidelines and approved by the institutional ethics review committee (70/9021).

Subject recruitment

Patients with genetically and clinically confirmed CADASIL (n=20) were recruited from the Neurovascular Genetics clinic, Queen Elizabeth University Hospital, Glasgow. Healthy controls were volunteers at the OHRI (n=11). Under local anaesthetic, all subjects underwent a gluteal biopsy from which intact small arteries (<200 μm diameter) were dissected from subcutaneous fat. These arteries were used for functional, structural and mechanical studies by wire and pressure myography, and VSMCs were isolated for primary cell culture, as previously described (35, 57) and summarized below. Identical protocols were used for CADASIL patients and control studies.

Pulse wave analysis in CADASIL patients

PWA was measured as an assessment of large vessel arterial stiffness using the Sphygmocor system, as previously described (15). Values were compared to published normal values for healthy control individuals (34).

Mouse model of CADASIL
The transgenic (Tg) mouse lines, TgNotch3\textsuperscript{WT} and TgNotch3\textsuperscript{R169C}, have been previously characterized and described (6). Briefly, TgNotch3\textsuperscript{WT} and TgNotch3\textsuperscript{R169C} mice (on an FVB background) express rat wild-type Notch3 and the CADASIL-causing Notch3(R169C) mutant protein, respectively, to a similar degree (approximately four-fold) compared with levels of endogenous Notch3 in non-transgenic mice (6). Mice were housed in individual cages in a room with controlled humidity and temperature (22°C - 24°C), and in light/dark cycles of 12 hours with free access to food and tap water. They were studied at 6 months of age, at which stage features of CADASIL are well established, as previously described (6, 16, 17, 58, 59). Mice were sacrificed at 6 months of age (at which age they exhibit features of the human disease), and blood and tissue were collected for experiments. Small mesenteric arteries were used to assess vascular function, structure and mechanics by wire and pressure myography. Aorta and mesenteric arteries were used to investigate Notch3 signalling and ER stress markers.

**Blood pressure measurement and echocardiography in mice**

Systolic blood pressure (SBP) was assessed by tail-cuff plethysmography (60). Mice were trained to the apparatus (Visitech Systems model BP-2000) for two consecutive weeks until stable readings were obtained. SBP measurements were assessed on the week prior to the start of the experimental protocols.

Cardiac function and structure were assessed by echocardiography using an Acuson Sequoia c512 ultrasound system to acquire non-invasive 2-D guided M-mode images at a 20 mm depth at the tip of the papillary muscles. Measurements were made in a short axis view using the leading edge-to-leading edge convention during both systole and diastole over at least three consecutive cardiac cycles. Echocardiographic indices assessed included Left Ventricular Anterior Wall thickness (LVAW), LV End-Diastolic Volume (LVEDV), LV End-Systolic Volume (LVESV), LV End Diastolic Diameter (LVEDD), LV End-Systolic
Diameter (LVESD), Fractional Shortening (FS) to assess left ventricular systolic function. 
Early (E) and late (atrial; A) ventricular filling velocity were calculated from measuring 
blood velocities across the mitral valve during each cardiac cycle. E/A ratio was calculated as 
an indirect measure of diastolic function. Ejection fraction (EF) = [(LVEDV – LVESV) / 
LVESD x 100]; Fractional shortening (FS) = [(LVEDD – LVESD) / LVEDD x 100].

**Human and mouse vascular functional studies**

Gluteal biopsies of subcutaneous fat measuring approximately 2cm x 1cm x 1cm were 
obtained under local anaesthetic. Small arteries were dissected from gluteal fat, cut into 2 mm 
ring segments (34, 57). Small arteries were also dissected from mesenteric arteries isolated 
from TgNotch3\textsuperscript{WT} and TgNotch3\textsuperscript{R169C} mice, as previously described (57). Briefly, arterial 
segments were mounted on isometric wire myographs (Danish Myo Technology, Denmark) 
filled with 5ml of physiological saline solution [(in mmol/L: 130 NaCl, 14.9 NaHCO\textsubscript{3}, 4.7 
KCl, 1.18KH\textsubscript{2}PO\textsubscript{4}, 1.17 MgSO\textsubscript{4}.7H\textsubscript{2}O, 5.5 glucose, 1.56 CaCl\textsubscript{2}.2H\textsubscript{2}O, and 0.026 EDTA] 
and continuously gassed with a mixture of 95% O\textsubscript{2} and 5% CO\textsubscript{2} while being maintained at a 
constant temperature of 37±0.5\textdegree C. Following 60 minutes of equilibration, the contractile 
responses of arterial segments were assessed by the addition of KCl (62.5mmol/L). The 
integrity of the endothelium was verified by relaxation induced by Ach (10\textsuperscript{-5} mol/L) in 
arteries pre-contracted with PE (10\textsuperscript{-6} mol/L). Endothelium-dependent relaxation was assessed 
as a dose-response to Ach (10\textsuperscript{-9}-3x10\textsuperscript{-5} mol/L) in human vessels. Endothelium-independent 
vasorelaxation was assessed by a dose-response to SNP (10\textsuperscript{-6} - 10\textsuperscript{-5} mol/L) in human vessels. 
Concentration-response curves to phenylephrine and angiotensin II (Ang II) (10\textsuperscript{-9} – 3x10\textsuperscript{-5} 

mol/L) were performed to evaluate vasoconstriction in human arteries (60).

TgNotch3\textsuperscript{WT} and TgNotch3\textsuperscript{R169C} mouse vascular responses to SNP were performed in 
mesenteric arteries pre-contracted with U46619 (3x10\textsuperscript{-8} mol/L). Vascular functional
responses to SNP were also assessed in the absence and presence of 4-PBA \((10^{-3} \text{ mol/L, 30 minutes})\) or fasudil \((10^{-6} \text{ mol/L, 30 minutes})\).

**Vascular structure and mechanical properties in human and mouse small arteries**

Additional arterial segments (~ 4 mm long) from CADASIL patients and control subjects and TgNotch3\(^{WT}\) and TgNotch3\(^{R169C}\) mice were studied as pressurized preparations using a Pressure Myograph System (110P system; Danish Myo Technology, Denmark) in Ca\(^{2+}\)-free physiological saline solution where intramural pressure was set to 70 mmHg for 30 minutes to allow vessels to equilibrate and to generate a variable degree of myogenic tone. Vessels were subjected to an increasing intramural pressure gradient, ranging from 10 to 120 mmHg at 5 minutes intervals. Internal and external vessel wall measurements were recorded and used to calculate structural and mechanical properties, as previously described \((26, 60)\).

Briefly, from internal \(D_i\) and external \(D_e\) diameter measurements in passive conditions, the following structural parameters were calculated: Wall thickness \((WT) = (D_e - D_i) / 2;\) Media:lumen ratio \(= (D_e - D_i)/2 D_i;\) Circumferential wall strain \(= (D_i - D_0)/D_0,\) where \(D_0\) is the internal diameter at 10 mmHg and \(D_i\) is the observed internal diameter for a given intravascular pressure, both measured in Ca\(^{2+}\)-free physiological saline solution; Circumferential wall stress \(= (P \times D_i)/(2WT),\) where \(P\) is the intraluminal pressure (1 mmHg \(= 1.334 \times 10^3\) dynes/cm\(^2\)) and \(WT\) is measured at each intraluminal pressure in Ca\(^{2+}\)-free physiological saline solution.

**Human vascular smooth muscle cell isolation**

Methods for the isolation and culture of human VSMCs have been previously described \((57)\). Briefly, cleaned arteries were placed in Ham’s F-12 culture medium containing 1% gentamicin, collagenase (type 1), elastase, soybean trypsin inhibitor and BSA, and were incubated for 1 hour at 37°C under constant agitation. The digested tissue was further dissociated by repeated aspiration through a syringe with 20G needle. The cell suspension
was centrifuged (2000 rpm, 4 minutes) and the cell pellet was resuspended in Ham’s F-12 culture medium containing 10% FBS. Cells were seeded onto 25mm round glass coverslips. For the first 48 hours, cells were incubated in Ham’s F-12 culture medium containing 10% heat-inactivated fetal calf serum. Thereafter, VSMCs were maintained in 231 media containing smooth muscle growth supplement (Thermo Fisher, Glasgow, UK) with penicillin/streptomycin. Before experimentation, cells were rendered quiescent by maintenance in a reduced growth supplement medium (0.5% FBS) for 18 hours. Only primary, low passage cells (passages 2 to 6) were studied. In some protocols, the role of ER stress, Rho kinase and Notch signalling was assessed using pharmacological inhibitors: ER stress inhibitor, 4-phenylbutyrate (4-PBA, 10⁻³ mol/L, Sigma-Aldrich, UK), Rho kinase inhibitor, fasudil (10⁻⁵ mol/L, Tocris, UK) and Notch inhibitor, gamma-secretase inhibitor XXIII (GSI, 5 µmol/L, Calbiochem #565792, UK). Cells were pre-exposed to 4-PBA, fasudil or GSI for 24 hours.

**Cell proliferation**

The fluorescein-based dye 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) (CellTrace™, Thermo Fisher, UK) was used to assess proliferation of cultured VSMCs. CSFE is a fluorescent cell-staining dye used to monitor cell proliferation due to the progressive halving of CFSE fluorescence within daughter cells following each cell division. VSMCs were detached from culture plates using 0.04% Trypsin/0.03% EDTA (PromoCell GmbH, Germany) and were then incubated with 5x10⁻⁶ mol/L CFSE in 1 mL of PBS for 30 minutes at 37°C. Cells were then resuspended in complete media 231 and washed twice. CFSE-labelled VSMCs were plated at 30% confluence and cultured for 4 days in media 231, supplemented with SMGS at 50% level. After this period, cells were detached from the plates with 0.04% Trypsin/0.03% EDTA and resuspended in 1% bovine serum albumin in PBS. Flow cytometry analysis with Ex/Em 492/517nm filters was performed using the FACS.
CANTO II system (BD Biosciences, USA), using acquisition FACS DIVA software v6.1.3 (BD Biosciences, USA). Data acquisition was analysed using the FlowJo X software (TreeStar, Ashland, USA).

**Apoptosis assay**

Apoptosis was assessed by caspase 3/7 activity measured using the Caspase-Glo 3/7 Assay kit (Promega, USA) according to manufacturer’s instruction. Briefly, 1000 VSMCs/well were seeded into Thermo Scientific White Opaque 96-Well Microplates (Pierce, Thermo Scientific, UK), respectively, and cultured for 3 hours to allow cells to adhere. The cells were then washed with PBS and the medium replaced with 50µl Opti-MEM and incubated for 24 hours. An equal volume of the Caspase-Glo 3/7 substrate was added to each well of the cell culture plate and mixed well using a microplate vortex mixer at maximum setting for 5 mins to ensure cells were lysed. The plate was then incubated at room temperature for one hour before reading cell luminescence.

**Phalloidin staining**

Cytoskeletal organisation was assessed using phalloidin staining (Cytoskeleton, USA) according to the manufacturer’s instructions. Briefly, VSMCs were fixed with 2% paraformaldehyde (PFA) in PBS at room temperature for 20 minutes, PFA was removed, cells were washed three times with PBS and non-specific binding sites were blocked with 1% FBS in PBS for 30 minutes at room temperature followed by incubation with phalloidin stain (10⁻⁷ mol/L) in 1% FBS in PBS for 30 minutes in a humidified chamber in the dark. Cells were then washed three times with PBS and mounted on glass slides using Prolong medium with DAPI (Thermo Fisher, UK). Fluorescence imaging was performed using a Zeiss confocal imaging system (LSM500). DAPI was excited at 405 nm and phalloidin at 535 nm. Images were acquired using Zen Pro (Zeiss, UK). Each experimental group was imaged in duplicate with a minimum of 40 images being analysed by two blinded observers using a
previously described protocol (61) as follows: 1, “intact” filamentous structures in most cells (rare or no “damaged” fibrils); 2 (mild), more intact filamentous structure than damaged structures; 3 (moderate), more damaged structure than intact; and 4 (severe), predominantly damaged structures (few intact fibrils). Intact was defined as discernible, distinct and organised filaments and damaged referred to disorganized, disarrayed, aggregated, clumped, or indiscernible structures.

**Quantitative real-time Polymerase Chain Reaction**

Quantitative real-time Polymerase Chain Reaction (qPCR) (Qiagen, UK) was used to assess expression of Notch3 target genes (*Hes5* and *HeyL*) and ER stress genes (*AMFR6, EDEM1, FBXO6, MBTPS1, VIMP* and *SYVN1*) in control and CADASIL VSMCs. mRNA expression of *Notch3, Hes5* and *HeyL* was also measured by qPCR in aorta and mesenteric arteries isolated from TgNotch3*WT* and TgNotch3*R169C* mice. Rho GEFs LARG, p115 and PDZ gene expression was also analysed in aorta from TgNotch3*WT* and TgNotch3*R169C* mice. For some experiments, wildtype FVB mice were used as a control for Notch3 and Notch3 target gene expression since TgNotch3*WT* and TgNotch3*R169C* mice were on a FVB background. Briefly, total RNA was extracted from tissues using TRIzol (Qiagen, Manchester, UK), treated with RNase-free DNase I, and 2 μg of RNA was reverse transcribed in a reaction containing 100 μg/mL oligo-dT, 10 mmol/L of 2’-deoxynucleoside 5’-triphosphate, 5×first-Strand buffer, and 2 μL of 200-U reverse transcriptase. For real-time PCR amplification, 3 μL of each reverse transcription product were diluted in a reaction buffer containing 5 μL of SYBR Green PCR master mix and 300 nmol/L of primers in a final volume of 10 μL per sample. The reaction conditions consisted of 2 steps at 50°C for 2 minutes and 95°C for 2 minutes, followed by 40 cycles of 3 steps, 15-second denaturation at 95°C, 60-second annealing at 60°C, and 15 seconds at 72°C. Mouse primers used are detailed in supplementary table 1. Data are expressed as target gene/GAPDH housekeeping gene. Relative gene expression was
calculated by 2ΔΔCt method, and the results reported as arbitrary units relative to the control conditions. RT2 primer sets (Qiagen, UK) were used (proprietary primers, sequence not disclosed). Human GAPDH, Nrip2 and Grip2 primers sequences are as follow: Forward: GAGTCAACGGATTTGGTCGT; Reverse: TTGATTTTGAGGGATCTCG; Forward: GTTCCTGCACAAGGACTCGG; Reverse: AGGCGTCTTTGGATCACACTG and Forward: GCAGGGGAGACAATAGGAAC; Reverse: CACAGTATCCTCGGAAC; respectively.

**Measurement of intracellular Ca^{2+} transients in VSMCs**

VSMC Ca^{2+} signalling was assessed using the fluorescent Ca^{2+} indicator, Cal-520 acetoxymethyl ester (Cal-520/AM; Abcam; 5x10^{-6} mol/L). Cells were grown in 6-well plates and following removal of culture media were incubated with 10^{-5} mol/L Cal-520 AM in 0.5% FBS at 37°C for 75 minutes followed by 30 minutes at room temperature. Following incubation, the dye solution was replaced with HEPES physiological saline solution (1.3x10^{-1} mol/L NaCl, 5x10^{-3} mol/L KCl, 10^{-3} mol/L CaCl, 10^{-3} mol/L MgCl, 2x10^{-2} mol/L HEPES, and 10^{-2} mol/L D-glucose, pH 7.4) for 30 minutes prior to imaging. VSMCs were stimulated with Ang II (10^{-7} mol/L) and the Ca^{2+} transient tracked for 5 minutes. In some experiments, VSMCs were pre-treated for 24 hours with 4-PBA or fasudil. Fluorescence-based measurements of Ca^{2+} signals were performed using an inverted epifluorescence microscope Axio Observer Z1 Live-Cell imaging system (Zeiss, UK) with excitation/emission wavelengths 490/525nm, respectively. Images were acquired and analysed using Zen Pro (Zeiss, UK).

**Immunoblotting**

Protein was extracted from cultured human VSMCs and from vessels isolated from TgNotch3^{WT} and TgNotch3^{R169C} mice. Protein (30μg) was separated by electrophoresis on a polyacrylamide gel and transferred to a nitrocellulose membrane. Non-specific binding sites
were blocked with 3% bovine serum albumin in Tris-buffered saline (TBS) solution. Membranes were then incubated with specific antibodies overnight at 4°C. Membranes were washed 3 times with TBS-Tween20 and incubated with infrared dye-labelled secondary antibodies for 1 hour at room temperature. Membranes were visualized using an Odyssey CLx infrared imaging system (LiCor Biosciences UK Ltd, UK) and results were normalized to β-actin protein and are expressed in arbitrary units. Antibodies used were as follows: anti-ROCK2 (1:500, 610623, BD Biosciences, UK), anti-ROCK1 (1:500; Chemicon International, UK), anti-PCNA (sc56, Santa Cruz, USA), anti-Bip (1:1000; 610978, BD Biosciences, UK), anti-Notch3 (1:2000; 5276, Cell signaling, UK), anti-β-actin (1:5000; A1978, Sigma-Aldrich, UK), anti-α-tubulin (1:10000, ab4074, Abcam, UK), anti-phospho-cofilin (3313S Cell signalling, UK); anti-phospho-vimentin (7391S Cell signalling, UK); anti-vimentin (3632S Cell signalling, UK); anti-phospho-filamin (4761S Cell signalling, UK); anti-filamin (4762S Cell signalling, UK), Nox5 (1: 1000; kindly provided by Prof. David Harrison, Vanderbilt University Medical Center, Nashville USA) (61).

**Rho kinase activity**

Rho kinase activity was measured with a Rho-associated kinase activity assay Kit (Merck, CSA001, UK), according to the manufacturer’s instructions. Briefly, VSMCs cells were lysed and 50 µL was placed in 96-well multi-strip plates and incubated for 30 minutes at 30 °C on an orbital shaker. Each microwell was washed 3 times with 1x wash buffer before an anti-phospho-MYPT1 (Thr696) antibody was added for 1 hour at room temperature. Wells were washed again, and a goat anti-rabbit IgG HRP secondary antibody added for 1 hour at room temperature, followed by a wash and the addition of chromogenic substrate tetramethylbenzidine (TMB) for 15 minutes. The reaction was stopped with ‘Stop Solution’ (Merck, UK) and absorbance at 450 nm was measured spectrophotometrically. Rho kinase
activity was normalised to protein content for each sample measured using the DC assay (BioRad, UK).

**Immunofluorescence staining of VSMCs**

For immunofluorescence analysis, VSMCs were plated and grown onto a microscope chamber slide (Ibidi, Germany). Cells were fixed in fresh 2% paraformaldehyde (PFA) for 20 minutes followed by washing with PBS. Unspecific binding was blocked with 5% BSA in PBS for 1 h at room temperature. Primary antibody incubation was performed overnight at 4°C with the following antibodies diluted in 0.2% BSA in PBS: Mouse monoclonal anti-Notch3ECD (Clone 1E4, 1:200, MABC594, Millipore, UK), rabbit polyclonal anti-alpha smooth muscle actin (1:200, ab5694, Abcam, UK). For detection Alexa Flour 488- and Alexa Flour 647-coupled secondary antibodies (Life Technologies) were diluted in 0.2% BSA in PBS and applied for 1 h at room temperature. A mouse IgG1 negative control antibody (Serotec, MCA928) was also used. After washing, vessels were mounted with Fluoroshield mounting medium containing DAPI (Abcam, ab104139). Images were captured by confocal microscopy (LSM880, Zeiss) using a 40x objective. The fluorescence mean value was determined using ImageJ (version 1.60, NIH).

**Lucigenin-enhanced chemiluminescence**

Lucigenin-enhanced chemiluminescence assay was used to determine NADPH-dependent ROS production in control and CADASIL VSMCs as we previously described (62). Cells were homogenized in lysis buffer (20 mmol/L of KH$_2$PO$_4$, 1 mmol/L of EGTA, 1 µg/mL of aprotinin, 1 µg/mL of leupeptin, 1 µg/mL of pepstatin, and 1 mmol/L of PMSF). 50 µl of the sample were added to a suspension containing 175 µl of assay buffer (50 mmol/L of KH$_2$PO$_4$, 1 mmol/L of EGTA, and 150 mmol/L of sucrose) and lucigenin (5 µmol/L). Luminescence was measured with a luminometer (AutoLumat LB 953, Berthold) before and after stimulation with NADPH (100 µmol/l). A buffer blank was subtracted from each
reading. The results are expressed in arbitrary units per milligram of protein, as measured by the BCA assay.

**Statistical analysis**

Data are expressed as mean±SEM unless otherwise stated. Statistical comparisons of parameters between groups were performed using two-tailed student's t-test, 1-way and 2-way ANOVA followed by Bonferroni post-hoc tests as appropriate. P <0.05 was considered statistically significant. Repeated measures ANOVA was used for comparison of groups within vascular reactivity studies. Data analysis was conducted using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA).
Author contributions
APH, KBN, ACM, FJR and RMT designed the experiments; APH, RAL, KBN, FM, PR, ANDC and FJR conducted experiments, acquired and analysed data; AJ, CD, RMT provided critical analyses of the manuscript; FM, CD and KM provided clinical information and access to patients; APH, KBN and RMT wrote the manuscript. The study was conceived and funding managed by RMT.

Acknowledgements
We thank Dr. Ying He and Elisabeth Beattie for helping with the myography experiments. We are also very grateful to the patients and volunteers who participated in this study.

Funding
The authors are funded by grants from the British Heart Foundation (BHF) (RE/13/5/30177) and the MRC (MC-PC-15076). The CADASIL biopsy samples were funded by grants from The Neurosciences Foundation and The Stroke Association (TSA 2013/02) and the control biopsy samples were funded by grants from the Department of Medicine, University of Ottawa and the Canadian Institutes of Health Research, Canada. RMT is supported through a BHF Chair award (CH/12/29762) and ACM is supported through a Walton Foundation fellowship, University of Glasgow.

Conflict of interest
The authors declare that there are no conflicts to declare.
References


Figures and figure legends

Figure 1. Reduced vasodilation and vasoreactivity in CADASIL arteries. Assessment of vascular functional responses in small arteries obtained from CADASIL and control subjects by wire myography. (a) Endothelium-dependent vasorelaxation in response to acetylcholine (ACh) and (c) Endothelium-independent vasorelaxation in response to the nitric oxide (NO) donor, sodium nitroprusside (SNP), were decreased in CADASIL vessels (n=6–17; Two-way ANOVA with Bonferroni post-test). (b) The impairment in ACh-induced vasodilatation observed in CADASIL were slightly ameliorated in vessels pre-treated with the ROS scavenger N-Acetyl Cysteine (NAC). (d) Maximum contractile responses (Emax) to phenylephrine (Phe) were also decreased in CADASIL vessels. (n=7–17; Student’s t test). Curves and bars represent the mean±SEM. *p<0.05 vs Control.
Figure 2. Vascular remodelling and altered mechanical properties in CADASIL arteries. Vascular structure and mechanical properties were assessed in pressurised small arteries obtained from CADASIL and control subjects. (a) External lumen diameter. (b) Lumen diameter. (c) Wall (media) thickness. (d) Media:lumen ratio. (e) Circumferential wall stress and (f) Circumferential wall at increasing intraluminal pressure (10-120 mmHg) in calcium-free conditions. (g) Vascular stress-strain curve (n=7–9; Two-way ANOVA with Bonferroni post-test). Curves represent the mean±SEM. *p<0.05 vs Control.
Figure 3. Mutant NOTCH3 gain-of-function in CADASIL VSMCs. (a) Representative immunofluorescence image of Notch3\textsuperscript{ECD} in CADASIL and control VSMCs were stained with anti-alpha smooth muscle actin (\(\alpha\)-SMA) and anti-Notch3\textsuperscript{ECD} antibodies. Objectives: 40x. Scale bars: 20 \(\mu\)m. Corresponding bar graphs represent the fluorescence intensity of at least five images from 3 control and 3 CADASIL patients. (b) Expression of Notch3 transmembrane/cytosolic fragment (TMIC). Upper panel, representative immunoblot. Lower panel, quantification of Notch3 TMIC protein levels. Protein expression was normalised to \(\beta\)-actin (\(n=7\)-8; Student’s \(t\) test). (c) NOTCH3 gene expression and expression of NOTCH3 target genes (d) HEYL, (e) Nrip2 and (f) Grip2 in CADASIL and control VSMCs in the absence and presence of a gamma-secretase inhibitor (GSI). Analysis was by qPCR and gene expression was normalised to GAPDH (\(n=5\)-8; Two-way ANOVA with Bonferroni post-test). Results are expressed as mean±SEM. *\(p<0.05\) vs Vehicle Control, #\(p<0.05\) vs Vehicle CADASIL.
Figure 4. Increased RhoA/Rho kinase activity and blunted [Ca\textsuperscript{2+}]\textsubscript{i} transients in CADASIL VSMCs. (a) VSMC Rho kinase activity assessed by ELISA (n=4-5; Student's \( t \) test). (b, c) Expression of ROCK2 (b) and ROCK1 (c) in CADASIL and control VSMCs in the absence and presence of a gamma-secretase inhibitor (GSI). Upper panels, representative immunoblots. Lower panels, quantification of ROCK2 and ROCK1 protein expression normalised to \( \alpha \)-tubulin (n=6-10; Two-way ANOVA with Bonferroni post-test). (d) Calcium transients were measured by live cell fluorescence imaging using the fluoroprobe Cal-520 AM. Representative tracings of VSMC [Ca\textsuperscript{2+}]\textsubscript{i} responses to Ang II (10^{-7} mol/L) in CADASIL and control groups. Experiments were repeated 4 times/group with >30 cells studied/field. (e) [Ca\textsuperscript{2+}]\textsubscript{i}, calculated as the area under the curve. Arrow indicates time of Ang II stimulation (n=4; Student's \( t \) test). Results are expressed as mean±SEM. *\( p<0.05 \), **\( p<0.01 \) vs Control.
Figure 5. Increased ER and oxidative stress in CADASIL VSMCs. ER stress-related genes were assessed by qPCR (a) AMFR6, (b) EDEM1, (c) FBXO6, (d) MBTPS1, (e) VIMP and (f) SYVN1. Results are normalized to GAPDH and expressed as mean±SEM (n=4-9; Student's t test). (g) Protein expression of Binding immunoglobulin protein (Bip) (ER stress marker) in CADASIL and control VSMCs in the absence and presence of GSI. Upper panel, representative immunoblot of Bip. Lower panel, quantification of Bip protein expression, normalised to α-tubulin (n=7; Two-way ANOVA with Bonferroni post-test). Results are expressed as mean±SEM. *p<0.05 vs Vehicle Control; #p<0.05 vs Vehicle CADASIL.
Figure 6. Nox5-derived ROS is an upstream regulator of Rho kinase and ER stress in CADASIL VSMCs. (a) Expression of Nox5 in CADASIL and control VSMCs in the absence and presence of a gamma-secretase inhibitor (GSI). Upper panels, representative immunoblots. Lower panels, quantification of Nox5 protein expression normalised to β-actin (n=6-10; Two-way ANOVA with Bonferroni post-test). (b) ROS production measured by lucigenin in CADASIL and control VSMCs in the absence and presence of GSI, fasudil and 4-PBA. Results are normalized by protein content (n=6-8; Two-way ANOVA with Bonferroni post-test). (c) Lucigenin in CADASIL and control VSMCs in the absence and presence of a Nox5 inhibitor (Mellitin). Results are normalized by protein content (n=6; Two-way ANOVA with Bonferroni post-test). (d) Expression of Bip in CADASIL and control VSMCs in the absence and presence of Mellitin. Upper panels, representative immunoblots. Lower panels, quantification of Bip protein expression normalised to β-actin (n=7; Two-way ANOVA with Bonferroni post-test). Results are expressed as mean±SEM. *p<0.05 vs Vehicle Control; #p<0.05 vs Vehicle CADASIL.
Figure 7. Interplay between Notch3, ER stress and Rho kinase in CADASIL VSMCs. Pre-treatment of VSMCs with 4-PBA (10⁻³ mol/L) or Fasudil (10⁻⁵ mol/L) reduced expression of (a) HEYL and (b) HES5, and ER stress-related genes (c) AMFR6 and (d) EDEM1 in CADASIL VSMCs without effect on control VSMCs (n=3-14; One-way ANOVA with Bonferroni post-test). (e) Increased expression of Bip in CADASIL VMSCs was reduced in 4-PBA (10⁻³ mol/L) and Fasudil (10⁻⁵ mol/L) pre-treated cells. Upper panel, representative immunoblot of Bip. Bip expression was normalized to β-actin (n=4-10; One-way ANOVA with Bonferroni post-test). (f) 4-PBA decreased Rho kinase activity in CADASIL VMSCs, as assessed by ELISA (n=4-12; One-way ANOVA with Bonferroni post-test). Results are expressed as mean±SEM. *p<0.05; **p<0.005 vs Vehicle group from control VSMCs.
Figure 8. ER stress inhibition and Rho kinase activity ameliorate VSMC cytoskeletal regulation in CADASIL. Phosphorylation of cytoskeletal-associated proteins, (a) vimentin, (b) coflin and (c) filamin was assessed by western blotting in CADASIL and control VSMCs in the absence and presence of 4-PBA ($10^{-3}$ mol/L) and fasudil ($10^{-5}$ mol/L). Representative western blots show phosphorylated forms of vimentin, coflin and filamin. Expression levels of phosphorylated vimentin and filamin were normalized to total vimentin and filamin while phosphorylated coflin was normalized to $\beta$-actin. Results are expressed as mean±SEM (n=4-7; One-way ANOVA with Bonferroni post-test). *p<0.05; **p<0.005 vs Control counterpart.
Figure 9. Vascular function and arterial remodelling in CADASIL mice. Assessment of vascular functional responses in mesenteric arteries from TgNotch3WT (TgN3WT) and TgNotch3R169C (TgN3R169C) mice were assessed by wire myography. (a) Endothelium-independent vasorelaxation in response to sodium nitroprusside (SNP). (b) Vasorelaxation in response to SNP in the presence of fasudil (10^-6 mol/L; 30 minutes), and (c) 4-PBA (10^-3 mol/L; 30 minutes) (Two-way ANOVA with Bonferroni post-test). Vascular structure was assessed in pressurised mesenteric arteries from TgN3WT and TgN3R169C. (d) External lumen diameter. (e) Lumen diameter. (f) Wall thickness. (g) Media:lumen ratio. (h) Cross-sectional area at increasing intraluminal pressure (10-120 mmHg) in calcium-free conditions. Curves represent the mean±SEM (n=6; One-way ANOVA with Bonferroni post-test). *p<0.05 vs TgN3WT; † p<0.05 vs TgN3R169C.
Figure 10. NOTCH3 signalling in mutant TgNotch3\textsuperscript{R169C} mice. (a) Upper panel, representative immunoblot of the NOTCH3 transmembrane/cytosolic (TMIC) fragment in aorta from TgNotch3\textsuperscript{WT} and TgNotch3\textsuperscript{R169C} mice; Lower panel, quantification of NOTCH3 TMIC protein levels. Protein expression was normalised to β-actin (n=6; Student's t test). (b) NOTCH3 gene expression and expression of NOTCH3 target genes HEYL and Hes5 in FVB-, TgNotch3\textsuperscript{WT}, and TgNotch3\textsuperscript{R169C} aorta (b, d, f) and mesenteric arteries (c, e, g), as assessed by qPCR. Gene expression was normalised to GAPDH (n=5-8; One-way ANOVA with Tukey's post-test). Results are expressed as mean±SEM. *p<0.05 vs TgNotch3\textsuperscript{WT}; ∞ p<0.05 vs FVB.
Figure 11. Increased vascular expression of Rho kinase and ER stress-related proteins in CADASIL mice. Protein levels were assessed by immunoblotting using aortas from TgNotch3\textsuperscript{WT} and TgNotch3\textsuperscript{R169C} mice. Results are normalized to β-actin and are expressed as mean±SEM (n=5; Student’s t test). The same β-actin loading control has been used in both figure 10A and 11A since the same membrane was re-probed for β-actin, NOTCH3 TMIC, and Bip. mRNA expression of the Rho GEFs PDZ (b), LARG (c) and p115 (d) in TgNotch3\textsuperscript{WT} and TgNotch3\textsuperscript{R169C} mice (n=6-7; Student’s t test). Gene expression is normalised to GAPDH. Results are expressed as mean±SEM. *p<0.05 vs TgNotch3\textsuperscript{WT}. 